Summary & Overview
HCPCS S3845: Genetic Testing for Alpha-Thalassemia
HCPCS Level II code S3845 represents genetic testing for alpha-thalassemia, a targeted molecular test to identify pathogenic variants that impact alpha-globin production. This code identifies a specialized laboratory service used to confirm carrier status, guide prenatal counseling, and support diagnostic evaluation for anemia or unexplained microcytosis. Nationally, alpha-thalassemia testing is important for preventing severe fetal outcomes and for genetic counseling in at-risk populations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and coding context, clinical use cases, and standard billing practices tied to this laboratory service. The publication highlights typical sites of service, common clinical indications, and the role of this code within broader genetic testing portfolios.
The report provides benchmarks where available, summarizes relevant policy considerations that affect reimbursement and utilization, and offers clinical context to help billing and compliance teams align claims submission with payer expectations. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3845 describes genetic testing for alpha-thalassemia. This service involves laboratory-based molecular analysis to detect genetic variants associated with alpha-thalassemia, a hereditary hemoglobinopathy that can affect hemoglobin production.
Service type: Genetic testing / molecular diagnostic testing
Typical site of service: Outpatient laboratory or clinical genetics laboratory setting
Clinical & Coding Specifications
Clinical Context
A 28-year-old pregnant woman of Southeast Asian descent presents for prenatal genetic evaluation after a routine complete blood count demonstrates microcytic anemia with low mean corpuscular volume and a partner screening indicating possible thalassemia trait. The obstetrics clinic orders genetic testing for alpha-thalassemia to determine carrier status and assess risk for Hb Bart's hydrops or hemoglobin H disease in the fetus. Specimen collection is performed in an outpatient phlebotomy clinic; the blood sample is sent to a molecular diagnostics laboratory for targeted alpha-globin gene deletion/sequence analysis. Results are returned to the ordering obstetrician and genetic counselor who review implications for pregnancy management, partner testing, and reproductive counseling.
Typical site of service: outpatient clinic (obstetrics/gynecology, maternal-fetal medicine), specialty laboratory performing molecular diagnostics.
Typical workflow: initial clinical assessment and CBC → genetic counseling and informed consent → specimen collection and S3845 billing for alpha-thalassemia genetic test → laboratory analysis (deletion testing and/or sequencing) → result reporting and post-test counseling; reflex or partner testing ordered if indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component |